Page 8 - Vaccine

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Bharat Biotech's TB vaccine MTBVAC begins clinical trials in India

The trials will assess the vaccine's safety, immune response, and efficacy in preventing TB in adults and adolescents. MTBVAC has been developed after research spanning over three decades

IVI commences tech transfer of oral cholera vaccine to Biological E

The tech transfer will be completed by 2025 and the vaccine will be manufactured for India and international markets by Biological E

ICMR study shows Covid vaccine not responsible for heart attacks: Govt

Answering a query, Mandaviya said there had been attempts to create misconceptions about Covid-19 vaccines

Takeda injects hope: Dengue vaccine clinical trials set to begin in India

Biological E will increase manufacturing capacity to up to 50 million doses a year, accelerating Takeda's plans to manufacture 100 million doses annually within the decade

Still facing strong headwinds, 2024 sales flat to lower, says Novavax

The company posted a larger-than-expected fourth-quarter loss as revenue lagged analysts' estimates, sending its shares down 26.3% to $4.44 in early trading

Global pharma companies dominate Indian vaccine market: PharmaTrac report

Global pharmaceutical companies hold 60% of value share in India's vaccine market, outperforming domestically manufactured vaccines in terms of revenue

More than half of world's countries will be at high measles risk: WHO

Death rates are higher in poorer countries due to weaker health systems, Crowcroft said, adding that outbreaks and deaths were also a risk for middle and high income countries

British Indian doctor to undertake 'ground-breaking' cancer vaccine trial

The trial will be available for just 44 patients around the world. After the trial finishes, the vaccine will either be licensed for use or if it's successful, a bigger study will be carried out

Novavax announces fresh round of layoffs, plans to reduce 12% of workforce

Novavax said the decision is part of its intention to bring down expenses below $750 million this year, which it had disclosed during its third-quarter earnings call in November

Serum Institute joins CEPI network to make vaccines for disease outbreaks

$30 mn invesment will expand company's ability to swiftly supply investigational vaccines for the Global South

IIL launches first indigenously developed Hepatitis A vaccine, 'Havisure'

Hepatitis A is a viral infection primarily spread through the fecal-oral route, meaning that it is transmitted through the ingestion of contaminated food or water

Third anniversary the of world's largest Covid vax drive: The inside story

It is important to counter the simplistic notion that Covid-19 vaccine development and production represented a significant new advancement

Oxford scientists launch first human vaccine trials for deadly Nipah virus

Scientists at the University of Oxford in the UK have launched first-in-human vaccine trials for the deadly Nipah virus which impacts many Asian countries, including India. The trials of the ChAdOx1 NipahB vaccine, will consist of 51 people aged 18 to 55, which will be led by the Oxford Vaccine Group. Nipah virus is a devastating disease that can be fatal in around 75 per cent of cases, the researchers said. Outbreaks have occurred in countries in Asia, including Singapore, Malaysia, Bangladesh and India, with a recent one in Kerala in September last year, they said. Nipah virus is carried by fruit bats and may also be transmitted by contact with infected animals (such as pigs) or from person-to-person via close contact, the according to the researchers. The virus, which is recognised by the World Health Organization as a priority disease requiring urgent research, belongs to the same family of paramyxoviruses as more well-known pathogens like measles, they said. Despite the firs

Moderna sales beat estimates at $6.7 bn last year on rising vaccine share

The company said Monday it still expects revenue to fall sharply this year to about $4 billion. It forecasts a return to sales growth in 2025 and to break even the following year

Shot stories: Meet Bharat Biotech's Krishna Ella, the man behind Covaxin

As the pandemic raged, India developed its own vaccine. Those weren't easy days, Ella, the man behind Covaxin, tells Sohini Das

Masks return as Singapore sees Covid-19 uptick, rise in hospitalisations

Covid-19 cases: The Singapore government stated that the dominant strain causing these infections has been identified as JN.1, a sublineage of BA.2.86

Role of media key to clearing myths, doubts about vaccines: Health expert

Media's role is crucial in creating awareness among people about government health services and also for clearing myths and doubts about vaccines, an expert said. Media can also play a key role in helping the West Bengal government and Unicef in carrying out 100 per cent immunisation drives in the state by spreading the message that vaccines are safe and effective in preventing diseases, Dr Suresh Thakur, health officer, UNICEF, West Bengal, said. "Media's role is very important in creating awareness among the general population about government health services and in clearing doubts on immunisation programmes," Thakur told PTI on the sidelines of a workshop on development journalism for healthcare issues held in Siliguri recently. The workshop was organised by Kolkata Press Club in collaboration with Unicef, West Bengal. "The media has done excellent work in the past to improve awareness and we look forward to their support in future too," the health officer said. Unicef regularl

Bharat Biotech, University of Sydney ink MoU for vaccine research

The international agreement aims to foster strong collaborations between sectors and organisations to develop innovative methods for tackling future epidemics and infectious diseases

Underdeveloped nations fighting drugmakers over access to TB, HIV drugs

South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. Experts see it as a shift in how such countries deal with pharmaceutical behemoths and say it could trigger more efforts to make lifesaving medicines more widely available. In the COVID-19 pandemic, rich countries bought most of the world's vaccines early, leaving few shots for poor countries and creating a disparity the World Health Organization called a catastrophic moral failure. Now, poorer countries are trying to become more self-reliant because they've realized after COVID they can't count on anyone else, said Brook Baker, who studies treatment-access issues at Northeastern University. One of the targets is a drug, bedaquiline, that is used for treating people with drug-resistant versions of tuberculosis. The pills are